NSCLC (Advanced Non-small Cell Lung Cancer)
Oncology·MeSH: Carcinoma, Non-Small-Cell Lung
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
5 drugs in development·4 companies·8 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| drug | ImmunityBio, Inc. (IBRX) |
Phase 2(2)
Phase 1(1)
| Drug | Company |
|---|---|
| ALX2004 | ALX ONCOLOGY HOLDINGS INC (ALXO) |
Phase 4(1)
| Drug | Company |
|---|---|
| 5-FU | Merus N.V. (MRUS) |
Compare drugs
Frequently asked questions
How many drugs are in development for NSCLC (Advanced Non-small Cell Lung Cancer)?
BioSniper tracks 5 drugs in development for NSCLC (Advanced Non-small Cell Lung Cancer) across 4 companies.
How many clinical trials target NSCLC (Advanced Non-small Cell Lung Cancer)?
There are 8 clinical trials targeting NSCLC (Advanced Non-small Cell Lung Cancer) tracked by BioSniper.
What is the prevalence of NSCLC (Advanced Non-small Cell Lung Cancer)?
The estimated prevalence of NSCLC (Advanced Non-small Cell Lung Cancer) is approximately 75.0 per 100,000 population.
Deep-dive into NSCLC (Advanced Non-small Cell Lung Cancer)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis